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Dear Editor,
First, we agree with Seto et al. regarding the impacts of 
the sensitivity of the detection methods of OBI (occult 
hepatitis B infection) prevalence but disagree regarding 
their idea on the lack of usefulness of anti-HBc screens. 
They have referred to Seo et al., who reported that the 
prevalence of anti-HBc positivity in Korea was 13.5%, 
whereas the prevalence of OBI was 0.016% (1). Anti-HBc is 
the ﬁrst antibody that is produced against HBV and is the 
most stable antibody (2); hence, the presence of the an-
tibody in individuals demonstrates introduction of HBV 
to the immune system via several mechanisms, includ-
ing transfusion (3, 4). Therefore, it seems that the rate 
of OBI among anti-HBc-positive persons is more than 
the anti-HBc-negative blood donors (5). During blood 
screening programs, hepatitis B surface antigen (HBsAg) 
testing, followed by polymerase chain reaction (PCR) as-
says, will be the most accurate approach of identifying 
OBI, but some blood transfusion services are unable to 
use PCR (based on high costs). We have proposed apply-
ing anti-HBc as a screening test for blood transfusion ser-
vices that are unable to use PCR to reduce the risk of PTH 
via OBI-infected blood and its components.
Second, Seto et al. have presented a nice mechanism 
for the possible cause for cryptogenic HCC in endemic 
chronic hepatitis B regions. They have described a good, 
probable mechanism of undetectable virological HBV 
markers in tumor histology. These mechanisms should 
be examined in future studies.
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